BridGene Biosciences Inc

BridGene Biosciences Inc. is a privately held biotechnology company based in San Jose, California. With a team of six employees, the company has generated $5 million in revenue. BridGene Biosciences is dedicated to discovering and developing innovative small molecules that target disease-causing proteins previously considered "undruggable" by traditional therapies. Their proprietary technology, IMTAC™ (Isobaric Mass Tagged Affinity Characterization), allows for the screening of small molecules against all proteins within live cells. This innovative platform enables the identification of drug candidates for high-value targets that have historically been challenging to address. The company's focus on previously undruggable targets holds significant potential for developing new therapies with novel mechanisms of action. BridGene aims to address unmet medical needs by expanding the range of treatable diseases and accelerating the drug discovery process. For more information about BridGene Biosciences and its innovative approach to drug development, please visit their website at bridgenebio.com.